In response to cancer chemotherapeutic drugs, cells rapidly trigger the apoptotic program or undergo growth arrest and senescence at specific phases of the cell cycle. Mitochondrial bcl-xL plays a central role in preventing alteration of mitochondrial dysfunction, cytochrome c release, caspase activation, DNA fragmentation and apoptosis. However, its pleitropic function depends on its subcellular localization. Here, we show that in addition to its mitochondrial effect that delays apoptosis, bcl-xL colocalizes and binds to cdk1(cdc2) during G 2 /M cellcycle checkpoint and its overexpression stabilizes a G 2 /Marrest senescence program in surviving cells after DNA damage. Bcl-xL potently inhibits cdk1(cdc2) kinase activity, which is reversible by a synthetic peptide between the 41st amino acid and 60th amino acid surrounding of the Thr47 and Ser62 phosphorylation sites, and Asn52 deamidation site, within the flexible loop domain of bclxL. A mutant deleted of this region does not alter the antiapoptotic function of bcl-xL, but impedes its effect on cdk1(cdc2) activity and on the G 2 /M-arrest senescence program after DNA damage. The nuclear interaction of bcl-xL and cdk1(cdc2) suggests that bcl-xL is coupled to the stabilization of a cell-cycle checkpoint induced by DNA damage, and this effect is genetically distinct from its function on apoptosis.
Introduction
Tissue homeostasis requires a carefully orchestrated balance between cell proliferation and cell death. Cells proliferate through a cell cycle, tightly regulated by cyclin-dependent kinase (cdk) activities (Morgan, 1995) .
Apoptosis eliminates unwanted cells by the coordinated activity of gene products that regulate and execute cell death. Genes of the Bcl-2 related family encode proteins that antagonize or promote cell death (Reed, 1998) . These proteins are found in the cytosol but most of them bear a C-terminal hydrophobic transmembrane domain responsible for their localization to subcellular organelles, including the mitochondria, endoplasmic reticulum and nucleus (Krajewski et al., 1993) . More recently, phosphorylated forms of Bcl-2 have also been localized in nucleoli together with nucleolin, cdk1(cdc2) and PP1 phosphatase at the onset of mitosis (Barboule et al., 2005) . Mitochondrial Bcl-2 related proteins play a central role in regulating apoptosis induced by a variety of death stimuli, including DNA damage caused by DNA topoisomerase I (20-S-camptothecin camptothecin lactone, CPT) and II (etoposide, VP-16) inhibitors. Alterations of mitochondrial functions, such as mitochondrial permeability transition, transmembrane potential disruption, ATP/ADP exchange and cytochrome c release, are early events involved in the initiation step of apoptosis induced by most chemotherapeutic agents (Zamzami et al., 1996; Kluck et al., 1997; Marzo et al., 1998; Matsuyama et al., 1998; Shimizu et al., 1999; Vander Heiden et al., 1999) . Bcl-xL (Boise et al., 1993) and several of its homologs modulate the chemosensitivity of cells by preventing or activating the mitochondrial events that lead to caspase activation. In addition, it has been reported that bcl-xL overexpression contributes to genetic instability, resulting in increased tetraploid cells (Minn et al., 1996) , and further investigations have revealed that bcl-xL and bcl-2 are parts of DNA damage response networks that influence cell-cycle checkpoints and DNA repair/recombination pathways (Komatsu et al., 2000; Saintigny et al., 2001) .
Cells trigger the apoptotic program or undergo growth arrest and senescence programs at specific phases of the cell cycle in response to DNA damage (Robles and Adami, 1998; Chang et al., 1999; Schmitt et al., 2002a) . The progression from G 2 into mitosis is regulated by the serine-threonine kinase cdk1(cdc2). Activation of cdk1(cdc2) requires association of the positive subunit cyclinB1 and phosphorylation of Thr161 by cdk-activating kinase (Draetta and Beach, 1988) . Before mitosis, the cyclin/kinase complex is also negatively regulated by phosphorylations at Thr14 and Tyr15, which are catalysed by inhibitory protein kinases, including Wee1, Myt1 and Mik1 (McGowan and Russell, 1995; Mueller et al., 1995; Booher et al., 1997) . Inhibition of cdk1(cdc2)-cyclinB1 kinase activity, by stabilizing the complex in an hyperphosphorylated state, has been shown to be involved in the G 2 /M cellcycle checkpoint after DNA damage (Lock and Ross, 1990) . Chk1 and chk2 are also important components of the DNA damage response pathways, and participate in S and G 2 /M phase checkpoints, in part by inactivation of cdk2 and cdk1(cdc2) through the inhibitory phosphorylation of cdc25a (Ser123), cdc25c (Ser216) and cdc25b (Ser230 and Ser563) (Furnari et al., 1997; Peng et al., 1997; Zeng et al., 1998; Schmitt et al., 2006) .
In this study, we found that in addition to its mitochondrial effect that delays apoptosis, bcl-xL colocalizes and binds to cdk1(cdc2) in the nucleus during G 2 /M cell-cycle checkpoint induced by DNA damage. Our observations suggest that bcl-xL in human cancer cells modulates the cell response to DNA damage, not only by delaying apoptosis, but also by stabilizing a cell-cycle checkpoint and senescence program in surviving cells.
Results
Effect of bcl-xL overexpression on cell death in the Namalwa cell line Human B lymphoma Namalwa cells that contain two nonsynonymous mutations in exon 7 of p53 (O'Connor et al., 1993b) showed hypersensitivity and apoptosis after short DNA-damaging drug treatments (Schmitt et al., 1998b (Schmitt et al., , 2000 . Namalwa cells overexpressing bcl-xL presented marked resistance to apoptosis induced by various cytotoxic drugs, including CPT, VP-16, cisPT and tumor necrosis factor alpha (TNF-a) (Figure 1a ). Bcl-xL overexpression inhibited mitochondrial cytochrome c release (Figure 1b and morphological changes typical of apoptosis ( Figure 1d ). Overexpressed bcl-xL conferred complete protection from cell death for at least 48 h in transfected Namalwa-bcl-xL cells. Some caspase activation and oligonucleosomic DNA fragmentation typical of apoptosis were detected 60-72 h after CPT treatment (Figure 1f ). However, morphological change analysis showed 25-30% apoptotic cells, 20-25% necrotic cells, and the remaining 45-55% cells with no signs of cell death 72 h post-treatment (Figure 1g ).
Effect of bcl-xL overexpression on cell-cycle progression in CPT-treated cells and its interaction with cdk1(cdc2)-cyclinB1 complexes. Treatment of cells with CPT, a DNA topoisomerase I inhibitor that stabilized a prelethal transient covalent intermediate between DNA and topoisomerase I, results in S phase slowing and subsequent G 2 /M arrest (Cliby et al., 2002) , or in rapid activation of apoptosis (Bertrand et al., 1993) . Namalwa cells undergo rapid activation of apoptosis after CPT treatment, with cells dying during S and G 2 /M phases of the cell cycle (Supplementary Figure 1) . By blocking apoptosis activation in response to CPT-induced DNA damage, overexpressed bcl-xL allowed Namalwa cells to undergo a cell-cycle checkpoint. The flow cytometry profiles in Figure 2a show that CPT-induced DNA damage in untransfected cells, rapidly led to the appearance of a sub-G 1 population of apoptotic cells, whereas Namalwa-bcl-xL cells progressed slowly in the late S/early G 2 phase of the cell cycle and accumulated at the G 2 /M boundary ( Figure 2a) . Expression of cyclinA/B1 and phosphorylation of cdk1(cdc2) are key regulators involved not only in the control of both S phase progression and the onset of mitosis during normal cell division (Draetta and Beach, 1988) , but also in DNAdamaged cells (Lock, 1992) . Slow S phase progression and accumulation of Namalwa-bcl-xL cells at the G 2 /M boundary was associated with the appearance of the slower, hyperphosphorylated, inactive form of cdk1(cdc2) and increased expression of cyclinA and B1 (Figure 2b ). Cdk1(cdc2)-associated histone H1 kinase activity decreased with time in CPT-treated, bcl-xLtransfected cells (Figure 2c ), consistent with DNA damage-induced cell-cycle arrest. Figure 1 Effect of bcl-xL overexpression on cell death in the Namalwa cell line. Cells, cellular extracts and assays were processed as described in Materials and methods. (a) The kinetics of DNA fragmentation were determined after treatments with various concentrations of camptothecin (CPT), etoposide (VP-16), cisplatin (cisPT) and TNF-a in untransfected ( ), mock-transfected ( ) and bcl-xL-transfected (m) Namalwa cells. Points represent the means7s.e. of three duplicate experiments. (b) Bcl-xL prevented cytochrome c release from mitochondria to cytosol after CPT treatment. (c) Cytochrome c release was associated with caspase activation (DEVDase activities; left graph) and oligonucleosome-sized DNA fragmentation (middle graph and ethidium-bromide stained upper gel) in CPT-treated Namalwa cells ( ); its retention in the mitochondria of CPT-treated Namalwa-Bcl-xL cells () correlated with non-activation of caspase (DEVDase activities; left graph) and oligonucleosome-sized DNA fragmentation (middle graph and ethidium-bromide stained lower gel). Points represent the means7s.e. of three independent experiments. (d) Electron micrograph of control and apoptotic (35-40%) CPT-treated Namalwa cells after 24 h. (e) Cellular morphology of control and CPTtreated Namalwa-Bcl-xL cells after 24 h; less than 1% of cells were apoptotic or necrotic. (f) Caspase activation (DEVDase activities) and occurrence of oligonucleosome-sized DNA fragmentation in CPT-treated Namalwa-Bcl-xL cells correlate with the kinetics of DNA fragmentation 72 h post-treatment. Points represent the means7s.e. of three independent experiments. (g) Cellular morphology observed by electron microscopy revealed that 25-30% of these cells underwent apoptosis, whereas 20-25% showed a necrotic mode of cell death 72 h after CPT treatment; 45-55% of these cells are viable.
Several studies provide some evidence that bcl-2-related proteins, including bcl-2, bcl-xL, mcl-1 and bad, can affect the control of cell-cycle regulation (Schmitt et al., 2002b) . More recently, bid, a BH3-only proapoptotic Bcl-2 family members, has also been reported to partially localize to the nucleus and to play role in the intra-S phase checkpoint downstream of DNA damage (Kamer et al., 2005; Zinkel et al., 2005) . Therefore, we investigated if overexpressed bcl-xL participates in cellcycle arrest after DNA damage. First, we asked whether the enforced expression of bcl-xL modifies cdk1(cdc2) or cyclinA/B1 nuclear localization after DNA damage, a parameter that plays a critical role in promoting G 2 /M transition (Pines and Hunter, 1991) . The nuclear and Bcl-xL and cell-cycle checkpoint E Schmitt et al cytosolic distribution patterns of cdk1(cdc2) and cyclinA/B1 were unaffected in cells overexpressing bcl-xL (data not shown). However, co-immunoprecipitation performed from nuclei-enriched fractions using anticdk1(cdc2) antibodies revealed the presence of hemagglutinin (HA)-bcl-xL within the immune complex ( Figure 2d ). Moreover, the amount of HA-bcl-xL coprecipitated with cdk1(cdc2) increased with time as the cells underwent the cell-cycle checkpoint after DNA damage ( Figure 2d ). To confirm these results, reciprocal experiments were performed in which HA-bcl-xL was immunoprecipitated from nuclei-enriched fractions. Bcl-xL and cell-cycle checkpoint E Schmitt et al
Analysis of the immune complexes with either a rabbit anti-cdk1(cdc2) antibody or a mouse anti-cdk1(cdc2) antibody, showed enhancement of cdk1(cdc2) co-precipitated with HA-bcl-xL after DNA damage ( Figure 2d ). In addition, HA-bcl-xL co-immunoprecipitated with cyclinB1 after CPT treatment (Supplementary Figure 2) . In colocalization experiments performed by immunofluorescence microscopy, HA-bcl-xL was found primarily into the cytosol in untreated cells, where it partially colocalized with inactive cytosolic cdk1(cdc2) (Figure 2e , upper panels). In contrast, a large amount of HA-bcl-xL was found in the nuclei of CPT-treated and G 2 /M blocked cells, where it unexpectedly colocalized with nuclear cdk1(cdc2) (Figure 2e , upper panels). Interestingly, these complexes were localized, and most likely trapped, within nucleolus, as HA-bcl-xL colocalized with the nucleolus marker, nucleolin ( Figure 2e , lower panels). Controls for fluorescence emission and non-specific overlap are showed in Supplementary  Figure 3 .
Endogenous bcl-xL translocates to nucleus and interacts with cdk1(cdc2) specifically in G 2 /M-arrested cells Because the above observations were done in HA-bclxL-transfected and overexpressed cells, we next explore the formation of protein complexes involving endogenous bcl-xL and cdk1(cdc2). We also performed these experiments in a second human cell line, the monocyticlike untransfected U937 cells and, using different drugs. First, we established conditions where these cells undergo G 1 arrest after a double aphidicolin block, G 2 /M arrest after VP-16 treatment and mitotic arrest (early metaphase) after nocodazol treatment (Figure 3a ). In the G 1 -and mitotic-enriched U937 cells, endogenous bcl-xL was found primarily into the cytosol, where it partially colocalized with inactive cytosolic cdk1(cdc2), more predominently in the mitotic-enriched cells (Figure 3b) . Strikingly, in G 2 /M-enriched cell populations, a significant amount of endogenous bclxL was found in the nuclei where it strongly colocalized with nuclear cdk1(cdc2) (Figure 3b ). Reciprocal coimmunoprecipitation studies performed from total or nuclei-enriched extracts confirmed those observations. Bcl-xL interacted with cdk1(cdc2) in total extracts obtained from G 2 /M-and mitotic-arrested U937 cell populations ( Figure 3c ), but nuclear interaction between endogenous bcl-xL and cdk1(cdc2) occurred exclusively in G 2 /M-arrested cells (Figure 3d ). Control markers for nuclei-enriched fractions are showed in Supplementary  Figure 4 . These results indicate that bcl-xL colocalizes with cdk1(cdc2) in nuclei during the G 2 /M checkpoint after DNA damage, when and where progression from G 2 to mitosis is normally regulated by active nuclear cdk1(cdc2)-cyclinB1 complexes to promote phase transition.
Bcl-xL inhibits cdk1(cdc2) kinase activity in vitro Inhibition of cdk1(cdc2)-cyclinB1 kinase activity, by stabilizing the complex in an hyperphosphorylated state, has been shown to be involved in the G 2 /M cellcycle checkpoint after DNA damage (Lock, 1992) . The enhanced interaction and nuclear colocalization between HA-bcl-xL and cdk1(cdc2) in G 2 /M-arrested bcl-xL-transfected Namalwa cells (Figure 2 ) and between endogenous bcl-xL and cdk1(cdc2) in G 2 / M-arrested untransfected U937 cells (Figure 3) , suggest that bcl-xL could modulate cdk1(cdc2) activity in G 2 /M cell-cycle checkpoint after DNA damage. To further address this question, we performed an in vitro kinase assay of immunoprecipitated cdk1(cdc2) kinase complexes incubated with histone H1 and various amounts of purified recombinant human bcl-xL protein lacking its C-terminal hydrophobic transmembrane domain (bcl-xLDTM). Bcl-xL(DTM) protein inhibited cdk1(cdc2) activity dose-dependently (Figure 4a ), whereas the buffered solution used in the purification protocol of bcl-xL(DTM) did not (Figure 4b) . A series of peptides covering the entire amino-acid sequence of bcl-xL(DTM) (Figure 4c ) was then utilized to confirm these observations. None of the peptides inhibited cdk1(cdc2) kinase activity significantly (Figure 4d ). However, a peptide (P03) corresponding to a fragment of the flexible loop within bcl-xL potently reversed the inhibitory effect of bcl-xL on cdk1(cdc2) kinase activity ( Figure 4e ). Together, these results revealed that bcl-xL bound to cdk1(cdc2) complexes and potently inhibited cdk1(cdc2) kinase activity. Moreover, these experiments also indicated that bcl-xL(DTM) was not phosphorylated by cdk1(cdc2) activity, suggesting that it was not a substrate (data not shown). The interaction of bcl-xL with the cdk complexes appears to involve a small amino-acid sequence between the 41st amino acid and 60th amino acid surrounding Thr47 and Ser62, and Asn52, phosphorylation and deamidation sites located within the flexible loop of bcl-xL, respectively. This amino-acid sequence (P03) is well conserved within bcl-xL of all species, but does not share homology with any other protein according to the National Center for Biotechnology Information Data Banks. Whether bcl-xL interacts directly with cdk1(cdc2) complexes or whether their association is mediated or enhanced by other cellular proteins or post-translation modifications is yet unknown. To monitor direct interaction between bcl-xL with cdk1(cdc2) or cyclinB1, a yeast two-hybrid system was used. Although bcl-xL interacted strongly with the BH3-only protein Bik (as control) in the yeast two-hybrid system, no interactions were detected between bcl-xL with cdk1(cdc2) or cyclinB1 (data not show). The concentration of bcl-xL(DTM) required to inhibit the kinase activity in vitro, and the lack of interaction in yeast two-hybrid system, could Figure 4 Bcl-xL inhibits cdc2/cdk1 kinase activity. Cells, cellular extracts and assays were processed as described in Materials and methods. (a) Histone H1 phosphorylation mediated by cdk1(cdc2) activity was inhibited by the addition of various concentrations of human recombinant bcl-xL(DTM) protein. Representative of three independent experiments. (b) Although the preparations of recombinant bcl-xL(DTM) protein were dialysed extensively after purification, the effect of various concentrations of imidazole was tested on cdk1(cdc2) kinase activity. Imidazole had no inhibitory effect on the rate of histone H1 phosphorylation. Representative of two independent experiments. (c) A series of peptides that covers all the amino-acid sequences of human bcl-xL(DTM) was synthesized. (d) None of these peptides (200 mM) had a direct effect on cdk1(cdc2) kinase activity. (e) The potency of these peptides (200 mM) in blocking the inhibitory effect of bcl-xL(DTM) (20 mM) on cdk1(cdc2) kinase activity was tested. Peptide 03 was the most potent in reversing the inhibitory effect of bcl-xL(DTM) on cdk1(cdc2) kinase activity. Representative of four independent experiments. (f) A deletion mutant of this region, between the 41st amino acid and 60th amino acid within the flexible loop domain of bcl-xL, named bcl-xL(DP03DTM), was generated and the corresponding recombinant protein was unable to inhibit cdk1(cdc2) activity (left panel) compared to bcl-xL(DTM) (right panel). Representative of four independent experiments. suggest that protein modification, including bcl-xL deamidation (Deverman et al., 2002) or phosphorylation level (Basu and Haldar, 2003; Du et al., 2005) , or its association with unknown partners could also participate and enhance the observed interaction. To confirm the importance of the small amino-acid sequence between the 41st amino acid and 60th amino acid within the flexible loop domain of bcl-xL, a deletion mutant of this region, named bcl-xL(DP03DTM) was generated and the corresponding recombinant protein purified. In contrast to bcl-xL(DTM), bclxL(DP03DTM) was unable to inhibit cdk1(cdc2) activity dose-dependently (Figure 4f ).
Bcl-xL stabilizes a G 2 /M-arrest senescence program, a function genetically distinct from its function in apoptosis To confirm the cell-cycle regulatory function of bcl-xL at the G 2 /M boundary of the cell cycle after DNA damage, and to assess the importance of the P03 small amino-acid sequence, we stably expressed HA-bclxL(DP03), and monitored its effect on apoptosis and cell-cycle arrest after CPT treatment in Namalwa cells. The level of HA-bcl-xL(DP03) expression in transfected Namalwa cells was comparable to the level of HA-bclxL expression (Figure 5a) , and its protective effect on cell death induced by CPT was similar to the protection conferred by HA-bcl-xL (Figure 5b) , significantly delaying the occurrence of apoptosis. These observations are consistent with previous findings indicating that the flexible loop domain of bcl-xL was nonessential for its antiapoptotic activity (Burri et al., 1999) . However, the long-term effect of HA-bcl-xL(DP03) on cell-cycle arrest after CPT treatment was different from that of HA-bcl-xL. Overexpressed HA-bcl-xL stabilized G 2 /M arrest and engaged the surviving cells (trypan blue-negative) in a G 2 /M-arrest long-term senescence program for at least 21 days post-treatment (Figure 5c ). In contrast, after initial perturbation of the progress of DNA replication and cell division that was visualized as a late S/early G 2 retardation, the surviving cells overexpressing HA-bcl-xL(DP03) showed broad G 1 peaks, suggesting that these cells completed one mitosis before entering into a G 1 -arrest long-term senescence program (Figure 5c ). These arrested cells expressed the senescence-associated b-galactosidase activity (Dimri et al., 1995) (Figure 5d ) and showed reduced metabolic activity, measured by the (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium reduction assay (MTT assay) (Figure 5d ), consistent with the expected reduction of metabolic activity in non-replicative senescent cells. To ensure that these cells stop to synthesize DNA, [ 3 H]-thymidine incorporation assays were performed. Supplementary Figure 5 shows that immediately following CPT exposure, DNA synthesis was inhibited to approximately 45-50% of the control untreated cells, and that following CPT removal, DNA synthesis recovered progressively to 75-80% control values within a 4 h period of CPT removal. These effects of CPT on DNA replication have been widely explored (Holm et al., 1989; Bertrand et al., 1992) . As the cells slowly progressed from S phase to G 2 /M (HA-bcl-xL), and through one mitosis before entering into G 1 arrest (HA-bcl-xL(DP03)), DNA synthesis was progressively inhibited to background level. Finally, the localization of HA-bcl-xL(DP03) was monitored by immunofluorescence microscopy after CPT. Although large amount of HA-bcl-xL was found in the nuclei with nuclear cdk1(cdc2) and nucleolin in CPT-treated and G 2 /Mblocked HA-bcl-xL-transfected Namalwa cells (Figure 2e ), or in VP16-treated and G2/M blocked U937 cells (Figure 3c ), HA-bcl-xL(DP03) was found predominently in cytosol in CPT-treated and G1 arrested HA-bcl-xL(DP03)-transfected cells (Figure 5e ). Similarly, attempts to co-immunoprecipitate cdk1(cdc2) with HA-bcl-xL(DP03), from nuclei-enriched fractions, were unsuccessfull (data not shown).
Discussion
This study suggests that beyond its apoptosis inhibitory function at the mitochondrial level, bcl-xL colocalizes in nucleoli with cdk1(cdc2) and stabilizes a G 2 /M cell-cycle checkpoint and G 2 /M-arrest senescence program after DNA damage. By binding to and inhibiting cdk1(cdc2) kinase activity, bcl-xL may contribute to the stabilization of G 2 /M cell-cycle arrest and the establishment of a long-term G 2 /M-arrest senescence program after CPT treatment. Previous studies have shown that prolonged, continuous treatment with CPT causes S-phase block, whereas short CPT treatment (30 min) produces S phase slowing and G 2 /M arrest associated with cdk1(cdc2)/ Figure 5 The effect of bcl-xL(DP3) on kinetics of apoptosis and cell-cycle checkpoint. Cells, cellular extracts and assays were processed as described in Materials and methods. Bcl-xL and cell-cycle checkpoint E Schmitt et al
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Bcl-xL and cell-cycle checkpoint E Schmitt et al cyclinB1 inactivation (Tsao et al., 1992; Yu et al., 2001; Cliby et al., 2002) . More recently, it has been suggested that after low-dose CPT treatment, cell-cycle arrest and senescence development are dependent on the p53/p21 pathway in human HCT116 colon cancer cells (Han et al., 2002) . Similar observations concerning the importance of the p53/p21 pathway have been reported with other chemotherapeutic agents or irradiation (Waldman et al., 1996; Bunz et al., 1998) . Likewise, studies with bleomycin, actinomycin D and cyclophosphamide have Bcl-xL and cell-cycle checkpoint E Schmitt et al revealed that cells respond to these chemotherapeutic agents by engaging a p53/p16-dependent senescence program (Robles and Adami, 1998; Schmitt et al., 2002a) . In contrast, others have reported senescence phenotypes in p53-mutated cell lines derived from various types of human solid tumors, including cervical, larynx and colon carcinoma, glioma and osteosarcoma . The similarity between the apoptotic phenotype and mitotic catastrophe resulting from unscheduled cdk1(cdc2) activation suggested that unscheduled cdk1(cdc2) activation may be a trigger of apoptosis. According to this hypothesis, unscheduled activation of cdk1(cdc2) kinase was shown to be a critical determinant of apoptosis induced by various stimuli, including DNA damage (Shi et al., 1994; Shimizu et al., 1995; Yao et al., 1996) . Using dominant-negative and temperaturesensitive cdk1 mutants or by overexpressing Wee1, a kinase that negatively regulates cdk1 by phosphorylating Tyr15, or by using excess peptide substrate to titer cdk1 activity, many investigators have reported that blocking cdk1 activity inhibits apoptosis induced by a variety of stimuli (Meikrantz et al., 1994; Shi et al., 1994; Meikrantz and Schlegel, 1996; Yao et al., 1996) . According to our study, trapping of cdk1(cdc2) with bcl-xL in nucleoli, and inhibition of cdk1(cdc2) kinase activity mediated by bcl-xL, could contribute to suppression of this apoptotic trigger or features of mitotic catastrophe.
Several observations support the existence of molecular connection and interface between cell death and cell-cycle regulation. In addition to its central role in controlling cell death, studies have associated bcl-2 with cell-cycle progression (Borner, 1996) , and this effect on cell proliferation was proven to be genetically distinct from its function on apoptosis (Vairo et al., 1996) . Mcl-1 is another Bcl-2 homolog known to function as an antiapoptotic protein (Kozopas et al., 1993) . Fujise et al. (2000) reported that mcl-1 inhibits cell-cycle progression through the S phase of the cell cycle. This function of mcl-1 is mediated partially through its interaction with proliferating cell nuclear antigen (PCNA), a cell-cycle regulator that plays a critical role in DNA replication. The binding motif for PCNA resides between the 221st amino acid and 228th amino acid of mcl-1. Mutations introduced within this region do not alter the antiapoptotic function of mcl-1, but impede its binding to PCNA and significantly reduce its effect on cell-cycle progression (Fujise et al., 2000) . More recently, it has been reported that a proteolytic fragment of mcl-1 exhibits nuclear localization and regulates cell proliferation via its interaction with cdk1(cdc2) (Jamil et al., 2005) . Similarly, bid, a BH3-only proapoptotic Bcl-2 family members, has also been reported to partially localize to the nucleus, to undergo ataxia-telangiectasia mutated (ATM)-mediated phosphorylation and to play unexpected role in the intra-S phase checkpoint downstream of DNA damage (Kamer et al., 2005; Zinkel et al., 2005) .
Microtubule inhibitors widely used in cancer chemotherapy, including paclitaxel, taxotere, vinblastine and vincristine, induce mitotic arrest linked with bcl-2, bcl-xL and mcl-1 phosphorylation (Haldar et al., 1996; Blagosklonny et al., 1997; Poruchynsky et al., 1998) . However, further studies have revealed that bcl-2 (Ser70, Ser87, Thr69) and bcl-xL (Thr47, Ser62) phosphorylation within their flexible loop domains is tightly linked with normal mitotic events (Ling et al., 1998; Scatena et al., 1998; Domina et al., 2000; Fan et al., 2000; Kharbanda et al., 2000) , raising the hypothesis that these proteins could have a role at the G 2 /M boundary (Yamamoto et al., 1999) . In addition, deamination of Asn52 and Asn66 has been reported to modulate bcl-xL activity after DNA damage (Deverman et al., 2002) . The importance of the region between the 41st amino acid and 60th amino acid surrounding these phosphorylation and deamination sites within the flexible loop domain of bcl-xL, is highlighted in our study. Although not necessary for bcl-xL anti-apoptotic function (Burri et al., 1999) , our results suggest that this region is essential to stabilize G 2 /M arrest after DNA damage, supporting the hypothesis that bcl-xL plays role in the G 2 /M checkpoint.
Our study demonstrates a nuclear colocalization and biochemical interaction between bcl-xL and cdk1(cdc2) coupled to a functional biological effect in response to DNA damage. Conceivably, our observation could imply that bcl-xL also plays a dominant role in the context of a physiological cell-cycle checkpoint during development. The mouse Bcl-x À/À phenotype was reported to be severe with mice dying at embryonic day 13 with extensive cell death in post-mitotic immature neurons in the developing brain and with severely shortened lifespan of immature lymphocytes (Motoyama et al., 1995) . Although the possibility of a functional link between the abnormalities in bcl-xdeficient mice and the weakness of a physiological cellcycle checkpoint during development remains to be elucidated, this study, with others, support the concept that bcl-xL stands at the crossroads of several DNA damage response pathways, including cell-cycle checkpoints, DNA repair, senescence and programmed cell death.
Materials and methods
Cell culture, transfection and drug treatments Human Namalwa and U937 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA), and the procurement of stable Namalwa cells transfected with pCEP4-HA-Bcl-xL or pCEP4-HA-mock vectors has been described previously (Schmitt et al., 1998b) . The mutant pCEP4-HA-Bcl-xL(DP3) vector, that lacks bcl-xL nucleotide sequences from 121 to 180, was generated by a triple polymerase chain reaction (PCR). The first fragment was amplified by Vent polymerase, using specific adapter primers containing NotI sequences at the ATG start codon (5 0 -GCG GCCGCATGTCTCAGAGCAACCGGGAG-3 0 ) and antisense junction primers corresponding to the flanking sequences at each deletion site (5 0 -ATTCACCGCGGGGCTGTCCCCT TCTGGGGCCTCAGT-3 0 ). The second fragment was amplified by Vent polymerase, using sense junction primers corresponding to the flanking sequences at each deletion site (5 0 -ACTGAGGCCCCAGAAGGGGACAGCCCCGCGGTG AAT-3 0 ) and adapter antisense primers containing NotI sequences at the TGA stop codon (5 0 -GCGGCCGCTCA TTTCCGACTGAAGAGTGA-3 0 ). The two amplified fragments were gel-purified, heat-denaturated and slowly annealed on ice. After elongation by Taq polymerase for 10 min, the third PCR with specific adapter primers containing NotI sequences at the ATG start codon and TGA stop codon was used to amplify by the annealed fragments. The amplified fragment was first cloned in pCRII vector and then subcloned at the NotI restriction site in the eucaryotic episomal expression vector pCEP4 (Invitrogen, Carlsbad, CA, USA) that had been modified to include hemagglutinin epitopeTag sequences (HA-tag) and Kozak consensus sequences (Schmitt et al., 1998b) . Vectors were sequenced using vector internal primers. Purified pCEP4-HA-Bcl-xL(DP3) construct was transfected in Namalwa cells by electroporation at 0.27 kV (Gene Pulser, BioRad, Hercules, CA, USA). Transfected cells were grown under hygromycin B1 selection at 1.5 mg/ml for 2-3 months to obtain stable lines before performing the experiments. In wild-type and transfected Namalwa cells, 20-S-CPT lactone and VP-16 treatments were of 30-min duration, followed by incubation of the cells in drug-free medium. Cisplatinum (II) diamine dichloride, TNF-a, taxol and nocodazol treatments were continuous.
Cell death assays
The kinetics of DNA fragmentation (Figures 1a and 5b) were determined in [2-
14 C]-thymidine (59 mCi/mmol; ICN BioMedicals, Costa Mesa, CA, USA) pre-labeled cells by DNA filter elution assays, as described elsewhere (Schmitt et al., 1998b) . For subcellular fractionation and cytochrome c release assays (Figure 1b) , the cells were first swelled in deionized water for 4 min on ice. The samples were adjusted to 220 mM mannitol, 70 mM sucrose, 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 1.0 mM ethylenediaminetetraacetic acid and dounced on ice. Nuclei (1000 g, 15 min) and mitochondria (10 000 g, 15 min) were pelleted by sequential differential centrifugation. The supernatants were clarified further by centrifugation at 100 000 g for 60 min (S-100 fraction). DEVDase (Asp-Glu-Val-Asp protease) activities (Figure 1c and f) were measured by monitoring fluorescence continuously in a dual luminescence fluorometer, using, as substrate, acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC; Bachem Bioscience Inc., King of Prussia, PA, USA). Enzyme activities were determined as initial velocities and expressed as relative intensity/min/mg (Schmitt et al., 1998b) . To analyse oligonucleosome-sized DNA fragmentation (Figure 1c and f) , DNA was extracted and electrophoresis was undertaken in 1.6% agarose gel, with DNA being visualized by ethidium bromide staining. For electron microscopy ( Figure 1d, e and g ), the cells were fixed in 0.1 M Millonig's phosphate buffer containing 2.5% glutaraldehyde and stained with 2% uranyl acetate. Sections (500-700 Å ) were mounted on copper grids and stained with lead citrate. The samples were examined by transmission electron microscopy (Ziess Em10 CA; JFE Enterprises, Brookville, MD, USA). Approximately 200-250 cells/sample were studied by electron microscopy.
Flow cytometry analysis
Cells were fixed in ethanol 70% for 2 h at 41C, treated with 150 mg/ml RNase A (30 min, 251C), and then resuspended in phosphate-buffered saline (PBS). Propidium iodide (50 mg/ml) was added before cytofluorometry analysis. DNA content and cell-cycle distribution were analysed in Coulter EpicsXL flow cytometers (Figures 2a, 3a and 5c ).
Immunofluorescence microscopy
For colocalization experiments in Figures 2e, 3b and 5e , approximately 1.0 Â 10 5 HA-bcl-xL and HA-bcl-xL(DP03) Namalwa cells (control and CPT-treated cells), and U937 cells enriched at specific cell-cycle phase after aphidicolin (G 1 -enriched; 1.0 mM for 24 h, drug-free medium for 24 h, 1.0 mM for an additional 24 h), VP-16 (G 2 /M-enriched; 2.5 mM, 16 h) and nocodazol treatment (M-enriched; 0.5 mM, 16 h), were spread by cytocentrifugation on glass slides and fixed in icecold methanol:acetone for 2-3 min. For immunofluorescence microscopy, non-specific binding sites were blocked with 5% bovine serum albumin (BSA) in the presence of irrelevant antibodies (anti-goat immunoglobulin (Ig) G, 15 mg/ml; Vector Laboratories, Birmingham, CA, USA); then the slides were incubated sequentially with monoclonal anti-bcl-xL antibody (clone 44 # 610746, Transduction Laboratories, Mississauga, ON, Canada; 10 mg/ml), fluorescein-conjugated anti-mouse Ig (Amersham Bioscience, Baie D'urfe, QC, Canada; 1:25 v/v), polyclonal anti-cdc2 antibody (Ab-1, Oncogene Research Products, Boston, MA, USA; 10 mg/ml) or polyclonal antinucleolin antibody (C23/H-250, SantaCruz Biotechnology Inc, Santa Cruz, CA, USA; 10 mg/ml) and Red Texas-linked antirabbit Ig antibodies (Amersham Bioscience; 1:25 v/v). Each antibody was incubated for 45-60 min, followed by several washes in blocking buffer. Nuclei were stained with the DNA intercalator Hoescht 33342. The slides were then mounted with Vectashield mounting medium (Vector Laboratories). Images were generated with a Nikon Optiphot-2 microscope equipped with Omega Optical Emission/Excitation Filter Sets XF-21 (fluorescein isothiocyanate FITC), XF102-2 (Red Texas) and XF05-2 (Hoescht) and mounted with a thermoelectricallycooled charge-coupled device camera (Model DC330E, DageMTI Inc, Michigan City, IN, USA) hooked up to a personal computer. All images were analysed with Clemex Vision software (Version 3.0.036, Clemex, Longueuil, QC, Canada).
In Figure 5d , approximately 1.0 Â 10 5 control and CPTtreated Namalwa-Bcl-xL cells were spread at the indicated times by cytocentrifugation on glass slides and fixed in 3% formaldehyde buffered with PBS for 2-3 min, then washed with PBS. The cells were incubated in a staining solution containing 20 mM citrate-phosphate, pH 6.0, 150 mM NaCl, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 and 200 mM fluorescein di-b-D-galactopyranoside in a humidified chamber at 371C for 24 h in dark (Yang and Hu, 2004) . The cells were then mounted and visualized by fluorescence microscopy as described above.
Immunoblotting and co-immunoprecipitation
The following antibodies were used: anti-HA (clone 12CA5, Roche Molecular Biochemicals, Laval, Quebec), anti-Bcl-xL (B22630 and clone 44 # 610746 Transduction Laboratories, Mississauga, ON, USA; AF800, R&D System, Minneapolis, MN, USA); anti-cytochrome c (clone 7H8.2C12, PharMingen, Mississauga, ON, Canada), anti cdk1(cdc2) (Ab-1, Oncogene Research Products, Boston, MA, USA; clone 17, SantaCruz Biotechnology, Santa Cruz, CA, USA), anti-cyclinB1 (clone GSN-1, PharMingen; clone 2H1-H6, Oncogene Research Products), anti-cyclin A (clone EG7.1 and clone BF683, Oncogene Research Products) and non-specific normal rabbit IgG antibody (sc-2027, Santa Cruz Biotechnology). Peroxidase-labeled secondary antibodies were detected by enhanced chemiluminescence using reagents from Amersham Bioscience (Figures 1b, 2b and d and 5a) and SuperSignal West Dura Extended Duration Substrate from Pierce Biotechnology Inc. (Rockford, IL, USA) (Figure 3c and d) .
To prepare total protein extracts (Figures 2b, 3c and 5a ), the cells were extracted with lysis buffer containing 20 mM HEPES(KOH) pH 7.4, 120 mM NaCl, 1% Triton X-100, 1 mM sodium orthovanadate, 2 mM phenylmethylsulfonyl fluoride, 5 mM sodium pyrophosphate and a cocktail of protease inhibitors (Complete, Roche Molecular Biochemicals). Insoluble material was discarded after centrifugation (10 000 g; 20 min). In the co-immunoprecipitation experiments performed in Figure 3c , supernatants were incubated with 5 mM dithiobis[succinimidylpropionate] (DSP) cross-linker agent (Pierce Biotechnology, Rockford, IL, USA) and mixed for 30 min by rotation at room temperature. The cross-linking reaction was quenched by the addition of Tris pH 7.5 to a final concentration of 50 mM. For immunoprecipitation, 250 mg of proteins from these extracts were mixed with 3.0 mg of polyclonal anti-Bcl-xL antibody, or 1.0 mg polyclonal anticdk1(cdc2) antibody or 1.0 mg non-specific normal rabbit IgG antibody (sc-2027, Santa Cruz Biotechnology), followed by overnight incubation at 41C. Immunocomplexes were captured with a protein A-and G-Sepharose mixture and the covalent amide bonds created by the DSP cross-linker were cleaved by incubating the immunocomplexes in Leammli buffer containing 75 mM DTT for 30 min at 371C before electrophoresis.
To prepare nuclei-enriched extracts 25 Â 10 6 cells ( Figures  2d and 3d) were lysed for 5 min on ice without agitation in 0.3% Nonidet P-40 prepared in 10 mM HEPES(KOH) pH 7.4, 80 mM KCl, 20 mM NaCl, 5 mM MgCl 2 , 5 mM ethylene glycol bis(aˆ-aminoethylether)-N,N,N 0 ,N 0 ,-tetraacetic acid (EGTA), 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 1.0 mg/ml aprotinin and 10% glycerol. In Figure 2d experiments, nuclei were harvested by centrifugation at 1000 g for 10 min and lysed at 41C for 30 min with gentle agitation in 1% NP-40 PBS buffer containing 1% BSA, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate and 1.0 mg/ml aprotinin. Insoluble pellets were discarded by centrifugation (10 000 g; 10 min), and the supernatants were incubated for 3 h at 41C with antibodies. Immune complexes were trapped by protein A/G PLUS-Agarose before sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). These experiments were performed in triplicate. In Figure 3d experiments, nuclei were harvested by centrifugation at 1000 g for 10 min, resuspended in 10 mM Hepes(KOH) pH 7.4, 80 mM KCl, 20 mM NaCl, 5 mM MgCl 2 , 5 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 1.0 mg/ml aprotinin and 10% glycerol, and incubated for 30 min at room temperature with 5 mM DSP cross-linker agent (Pierce Biotechnology, Rockford, IL, USA). The crosslinking reaction was quenched by the addition of Tris pH 7.5 to a final concentration of 50 mM, before nuclei lysis performed lysed at 41C for 30 min with gentle agitation in 1% NP-40 PBS buffer containing 1% BSA, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate and 1.0 mg/ml aprotinin. For immunoprecipitation, 250 mg of proteins from these nuclear extracts were mixed with 3.0 mg of polyclonal anti-Bcl-xL antibody, or 1.0 mg polyclonal anticdk1(cdc2) antibody or 1.0 mg non-specific normal rabbit IgG antibody (sc-2027, Santa Cruz Biotechnology), followed by overnight incubation at 41C. Immunocomplexes were captured with a protein A-and G-Sepharose mixture and the covalent amide bonds created by the DSP cross-linker were cleaved by incubating the immunocomplexes in Leammli buffer containing 75 mM DTT for 30 min at 371C before electrophoresis.
Cdk1(cdc2) kinase assays Cdk1(cdc2) kinase activity (Figures 2c and 4a-f) was measured by immune complex kinase assay, using purified histone H1 as substrate (O'Connor et al., 1993a) . Reactions were carried out for 10 min at 371C in 20 mM Tris-HCl, 10 mM MgCl 2 , pH 7.5, 5 mM unlabeled ATP, 10 mCi [g 32 P]ATP (4500 Ci/mmol) and 3 mg histone H1 with or without various concentrations of purified recombinant bcl-xL(DTM), or bcl-xL(DP03DTM) or synthetic peptides. Kinase inhibition studies were performed in triplicate. Recombinant human bcl-xL(DTM) and bcl-xL (DP03DTM) proteins were produced and purified, as described previously (Schmitt et al., 1998a) , and the synthetic peptides were obtained from Research Genetics Inc. (Huntsville, AL, USA).
Abbreviations
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